As the only currently available treatment for the devastating child-onset disorder, Hunter’s Syndrome, enzyme replacement therapy (ERT) provides symptomatic relief only, and is not curative. Hunter’s Syndrome is characterized by progressive deterioration of physical condition and cognitive function, organ enlargement, severe stiffness of the joints, and a dramatic decrease in life expectancy. The relentless progression of Hunter’s Syndrome highlights the desperate demand for innovative regenerative methods of intervention. Current treatment methodologies do not begin to meet the desperate demands of patient care, motivating the medical community to explore advanced therapeutic options. Innovative approaches utilizing umbilical cord mesenchymal stem cells (UC-MSCs) may provide safer therapies for patients with complex genetic disorders. Families of children with severe genetic conditions must navigate complex international healthcare systems to obtain cellular therapies. The best stem cell clinic offers these therapies to properly implement and optimize advanced treatment options and therapeutic benefits for patients.
Pathology of Hunter’s Syndrome
Hunter’s Syndrome is presented by a critical deficiency of the enzyme iduronate-2-sulfatase. The lysosomal degradation of two glycosaminoglycans, dermatan and heparan sulfates, is a dual process that the best stem cell clinic aims to correct using UC-MSCs. Enzyme deficiencies result in massive lysosomal swelling and cellular homeostasis disruption through the unrelieved cellular degradation processes. These processes result in cellular apoptosis, lysis, and necrosis. Neurodegeneration is due to the effects of the massive heparan sulfate cellular accumulation in the central nervous system. Additionally, in Hunter’s syndrome, changed dynamics of the extracellular matrix disrupt signaling pathways and cause further degradation of tissues throughout the body. If the molecular degradation of the cellular matrix is not arrested by interventions like UC-MSCs provided by the best stem cell clinic, it will cause irreversible, catastrophic changes to the structure of the body’s major organs. It will also lead to progressive dysfunction of the heart, lungs, and muscles.
Standard Treatment Options
In the past, the only option available to physicians to alleviate some of the symptoms of Hunter’s Syndrome was to use enzyme replacement therapy. Enzyme replacement therapy consisted of intravenous administration of iduronate-2-sulfatase to help clear some of the accumulated glycosaminoglycans. While this approach helped some of the peripheral symptoms, it helped very little, if at all, with the central symptoms because large recombinant enzymes cannot cross the blood-brain barrier and thus do nothing to stop the progressive degeneration of the central nervous system. The enormous molecular size of the synthetic enzymes also precludes them from crossing the bound brain capillary endothelial cells. Another historical approach was to perform a hematopoietic stem cell transplantation, which provided an endogenous source of the missing enzyme, a method now being advanced upon by UC-MSCs at the best stem cell clinic. Unfortunately, the older transplantation is very aggressive, becomes a source of significant immunologic complications and is even fatal in some cases. Clearly, there is an urgent need to develop therapies that are safe and will have a greater impact on the peripheral and central symptoms of the disease.
Therapeutic Superiority
The major benefit of incorporating UC-MSCs into therapy at the best stem cell clinic is that it allows the first truly innovative therapy to treat Hunter’s Syndrome. Hunter’s Syndrome is an excellent candidate for this therapy because of the remarkable immunomodulatory effects of UC-MSCs, which allow them to treat systemic inflammation without causing an immune reaction, which is especially useful considering the fragile state of patients. Perhaps the greatest benefit of this therapy is that UC-MSCs have the ability to perform metabolic cross-correction.
Once introduced for Hunter’s Syndrome, UC-MSCs secrete active iduronate-2-sulfatase to the extracellular space. This enzyme is then captured by neighboring deficient cells using the mannose-6-phosphate receptors and restores lysosomal function. In addition, the UC-MSCs’ secretome is capable of stimulating extensive tissue regeneration. Their paracrine signaling is also coupled with the release of neurotrophic factors that initiate neurogenesis and reduce neuroinflammation. UC-MSCs possess the ability to assess their tissue microenvironment and concentrate their efforts at the site of severe tissue damage. Their exosomes are loaded with key microRNAs and proteins that initiate cell survival and restoration of injured neural pathways. Additionally, the unique exosomal transport systems allow the factors within to cross the blood-brain barrier, providing the means to reverse the formerly permanent cognitive deterioration. Seeking this advanced cellular intervention at the best stem cell clinic ensures that patients will be the first to obtain the most advanced regenerative treatments, as they utilize the most sophisticated processing methods.
Figure 1: Hunter’s Syndrome Treatment options
Future Clinical Trends
The future use of UC-MSCs to treat Hunter’s Syndrome in Thailand appears to be very bright. Thailand has become an international leader in setting up cutting edge biotechnological research and regenerative medicine. Thailand’s well-crafted and advanced cellular therapy regulations create safe and rapid entry pathways to advanced therapy. In addition, the combination of world class research facilities and well funded research attracts top tier researchers from across the globe. The best stem cell clinic in this area provides patients with the most advanced lab techniques and the optimal control and safety techniques. The combination of superior medical personnel in the field and top tier governmental support is the best setting for groundbreaking treatments for genetic disorders.
The use of UC-MSCs offers a multifunctional biological approach to systemic enzymatic deficiency and severe neurodegeneration in Hunter’s Syndrome. UC-MSCs utilize paracrine signaling, metabolic cross-correction, and immune modulation to create the possibility of restoring cellular homeostasis. The rapid development of regenerative biotechnology means that, in the near future, the best stem cell clinic will likely offer the greatest chance of successful interventions. The cellular-based approach being developed has the potential to completely alter the course of pediatric patients and will likely provide the greatest impact on the global approach to pediatric genetic disorders.